An analysis of the costs and treatment success of etanercept in juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children register
Objective. To analyse and report the costs and effects of etanercept therapy in patients with JIA. Methods. Forty-nine JIA patients were evaluated by means of the JIA core set at the start of etanercept and after 3, 15 and 27 months of therapy. At the same time-points, parents of the patients were asked to complete the Health Utility Index Mark 3 (HUI3). Direct medical costs were collected for 1 year before and 27 months after the start of etanercept and compared with gain in utility. Results. Mean total direct medical costs after the start of etanercept were on average 12 478 euros per patien... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | TEXT |
Erscheinungsdatum: | 2011 |
Verlag/Hrsg.: |
Oxford University Press
|
Schlagwörter: | CLINICAL SCIENCE |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-26633701 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | http://rheumatology.oxfordjournals.org/cgi/content/short/50/6/1131 |